Company / Cash & Equivalents
Cartesian Therapeutics, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$125.1M
FY2025
5-year range
$76.9M / $212.6M
FY2021-FY2025
Trend
-41.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 8 years, ranging from $17M in FY2016 to $213M in FY2024.
Based on SEC 10-K filings.
$125M in FY2025 with a 5-year CAGR of +6.8%.
Improved from $77M to $125M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +3.1%
- 5-Year CAGR
- +6.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +6.8%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 41.1% year-over-year.
- Peak cash & equivalents was recorded in FY2024.
- Lowest cash & equivalents in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -0.06 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $125.1M | -41.1% |
| FY2024 | $212.6M | +176.4% |
| FY2023 | $76.9M | -32.6% |
| FY2022 | $114.1M | -17.8% |
| FY2021 | $138.7M | +54.3% |
| FY2020 | $89.9M | +140.3% |
| FY2019 | $37.4M | +125.4% |
| FY2016 | $16.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026